YOLFTbeta
Biomind Labs Inc

Biomind Labs Inc

BMND · NEO · Healthcare / Biotechnology

0.355CAD-0.33 (-48.55%)

Price History

Full chart

Market Stats

Previous Close0.69
Open0.355
Day Range0.355 – 0.355
52-Week Range0.01 – 0.80
Volume0
Market Cap53.52M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta7.28
50-Day Avg0.2159
200-Day Avg0.1765

About

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's disease; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson's disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia; BMND03 for the treatment of addictive disorders; BMND05 to treat chronic pain; and BMND07 for the treatment of major depressive disorder. The company is headquartered in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Alejandro Antalich
  • Employees0
  • Headquarters515 ? 701 W. Georgia Street, Vancouver, BC, Canada, V7Y 1C6, Canada
  • Websitehttps://www.biomindlabs.com

Leadership

  • Mr. Alejandro AntalichCEO & Director · b. 1974
  • Mr. Oscar Alejandro León Bentancor CPACFO & Director · b. 1959
  • Ms. Paola Diaz Dellavalle Ph.D.Chief Scientific Officer
  • Mr. Juan PresaChief Legal Officer · b. 1991

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00000
Operating Income--3.43M-2.93M-991.43K-404.45K-846.60K
EBITDA--4.30M-2.94M-1.02M-218.91K-779.47K
Net Income--4.33M-2.99M-1.19M-260.48K-850.41K
R&D-570.95K574.44K306.95K16.06K0
Interest Expense03.71K1.36K161.39K32.65K68.71K

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-2.53M89.06K74.20K41.16K36
Total Liabilities-334.95K336.72K1.51M1.34M1.74M
Total Equity-2.19M-247.66K-1.43M-1.30M-1.74M
Cash-2.27M26.16K24.27K14736
Net Debt---715.06K670.53K728.45K

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.00M-2.12M-2.15M-765.93K-354.43K-67.55K
Investing Cash Flow-44.34K-44.34K----
Financing Cash Flow12.00M4.47M-38.52K762.45K302.25K86.34K
Capital Expenditure44.59K44.59K0000
Free Cash Flow--2.17M-2.15M-765.93K-354.43K-67.55K
FCF to OCF-102.10%100.00%100.00%100.00%100.00%

Key Statistics & Ratios

Market Cap53.52M
Enterprise Value54.69M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book129.78
EPS-0.01
Book Value-0.0321
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-811.08K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-498.21%
Return on Assets-2859.18%
Shares Outstanding77.57M
Shares Float49.41M
Beta7.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 28, 20211:32.5